Results 11 to 20 of about 10,485 (198)

Teriparatide Induced Delayed Persistent Hypercalcemia [PDF]

Case Reports in Endocrinology, 2014
Teriparatide, a recombinant PTH, is an anabolic treatment for osteoporosis that increases bone density. Transient hypercalcemia is a reported side effect of teriparatide that is seen few hours following administration of teriparatide and resolves usually
Nirosshan Thiruchelvam, Jaskirat Randhawa, Happy Sadiek, Gaurav Kistangari   +3 more
doaj   +2 more sources

Therapy of Osteoporosis in Men with Teriparatide [PDF]

Journal of Osteoporosis, 2011
Osteoanabolic therapy is an attractive therapeutic option for men with osteoporosis because it directly stimulates bone formation, an action not shared by any antiresorptive drug.
Natalie E. Cusano, Aline G. Costa, Barbara C. Silva, John P. Bilezikian   +3 more
doaj   +2 more sources

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide [PDF]

JBMR Plus, 2019
Teriparatide, currently only available in brand form in the United States, is a costly drug approved for the treatment of postmenopausal osteoporotic women who are at high risk of fracture.
Takahiro Mori, Carolyn J Crandall, David A Ganz   +2 more
doaj   +2 more sources

Response to teriparatide in Chinese patients with established osteoporosis: osteocalcin and lumbar spine bone-mineral density changes from teriparatide Phase III study

Clinical Interventions in Aging, 2017
Chunyan Lu,1 Yun Chen,2 Bin Zhang,2 Yu Chen,2 Fan Bai,2 Decai Chen1 1Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China; 2Lilly Suzhou Pharmaceutical Co.
Lu C, Chen Y, Zhang B, Chen Y, Bai F, Chen D   +5 more
doaj   +1 more source

Enhancement of ghrelin-signaling system by Rikkunshi-To attenuates teriparatide-induced pica in rats

Journal of Pharmacological Sciences, 2018
Teriparatide is clinically used for the treatment of osteoporosis; however, nausea is often observed in patients. Its insufficient control affects the ability to continue teriparatide therapy.
Kouichi Yamamoto, Yukihiro Isogai, Takayuki Ishida, Keisuke Hagihara   +3 more
doaj   +2 more sources

Bilateral healing of pseudofractures in hypophosphatasia with teriparatide: a case report [PDF]

Journal of Medical Case Reports
Background Hypophosphatasia is a rare, inherited metabolic bone disease characterized by impaired activity of tissue-nonspecific alkaline phosphatase leading to pathological mineralization of hard tissue, predisposing to poorly healing fractures. Limited
Elaf Al-Saoudi, Nicola Hepp, Jens-Erik Beck Jensen   +2 more
doaj   +2 more sources

Teriparatide use in osteopenic patients undergoing single-level lumbar fusion associated with decreased 2-year revision rates [PDF]

Journal of Craniovertebral Junction and Spine
Context: Low bone density is common among lumbar fusion patients and increases the risks of pseudarthrosis, hardware failure, and revision. Teriparatide improves bone mass and fusion in osteoporosis, but its benefit in osteopenia or normal bone remains ...
Mitchell K. Ng, Ariel N. Rodriguez, Abigail Razi, Ahmed K. Emara, Brian T. Ford, Ameer Tabbaa, Divya Gouni, Jacquelyn J. Xu, Paul G. Mastrokostas, Jad Bou Monsef, Afshin E. Razi   +10 more
doaj   +2 more sources

Short-term Teriparatide Delivery and Osseointegration: a Clinical Feasibility Study

Journal of Dental Research, 2011
Teriparatide is an anabolic osteoporosis therapeutic agent that can improve healing after fractures and periodontal surgeries. Clinical studies investigating the effects of teriparatide on the osseointegration of titanium implants have not been ...
Stefan Tangl, G Watzek, Reinhard Gruber   +2 more
exaly   +2 more sources

Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review

São Paulo Medical Journal
CONTEXT AND OBJECTIVE: Osteoporosis is defined as a disease characterized by low bone mass and deterioration of the bone tissue microarchitecture. Teriparatide stimulates the formation and action of osteoblasts, which are responsible for bone formation ...
Virgínia Fernandes Moça Trevisani, Rachel Riera, Aline Mizusaki Imoto, Humberto Saconato, Álvaro Nagib Atallah   +4 more
doaj   +2 more sources

Safety of daily teriparatide treatment: a post hoc analysis of a Phase III study to investigate the possible association of teriparatide treatment with calcium homeostasis in patients with serum procollagen type I N-terminal propeptide elevation

Clinical Interventions in Aging, 2015
Takanori Yamamoto,1 Mika Tsujimoto,2 Hideaki Sowa11Medical Science, Lilly Research Laboratories, Medicines Development Unit Japan, 2Asia Pacific Statistical Science-Japan, Science and Regulatory Affairs, LRL MDU-Japan, Eli Lilly Japan K.K, Kobe, Hyogo ...
Yamamoto T, Tsujimoto M, Sowa H
doaj   +1 more source